Funding for this research was provided by:
Foundation for the National Institutes of Health (R35NS105078, HG008986, UM1 HG006542)
Text and Data Mining valid from 2019-05-17
Received: 18 September 2018
Accepted: 9 April 2019
First Online: 17 May 2019
Ethics approval and consent to participate
: This research study of aggregate clinical genomics data was approved by the Baylor College of Medicine Institutional Review Board (protocol H-37568) and was conducted within the guidelines of the Declaration of Helsinki. The Baylor College of Medicine IRB (IORG number 0000055) is recognized by the US Office of Human Research Protections (OHRP) and Food and Drug Administration (FDA) under the Federal Wide Assurance program. The Baylor College of Medicine IRB is also fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
: Not applicable
: Baylor College of Medicine and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), formerly the Baylor Miraca Genetics Laboratories, which performs chromosomal microarray analysis and clinical exome sequencing. JRL serves on the Scientific Advisory Board of the BG. JRL has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple US and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. Yang is a member of the Scientific Advisory Board (SAB) of Veritas Genetics China. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.